Table 1 Biological and biochemical characteristics of the control group stratified by breast disease type: benign breast disease and stage 0 breast tumor
From: Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
Variable | Benign (n = 14) | Stage 0 (n = 9) | Two-group comparison | ||
|---|---|---|---|---|---|
|  | Mean  ± SD | Median  ± IQR | Mean  ± SD | Median  ± IQR | P-value |
Age (years) | 54 | 54 | 58 | 51 | 0.87‡ |
 ± 9 | [50; 62] |  ± 6 | [50; 60] | ||
BMI (kg/m2) | 26.0 | 26.0 | 24.0 | 23.9 | 0.28†|
 ± 4.9 | [21.1; 30.8] |  ± 3.0 | [22.7; 24.5] | ||
Cholesterol (mmol/L) | 5.0 | 4.8 | 5.2 | 5.3 | 0.59†|
 ± 1.0 | [4.4; 5.9] |  ± 0.4 | [5.0; 5.3] | ||
Triglycerides (mmol/L) | 1.8 | 1.5 | 1.1 | 1.0 | 0.15‡ |
 ± 1.1 | [1.0; 2.0] |  ± 0.3 | [0.8; 1.4] | ||
HDL-C (mmol/L) | 1.3 | 1.3 | 1.8 | 1.8 | 0.01†* |
 ± 0.4 | [1.1; 1. 6] |  ± 0.4 | [1.4; 2.2] | ||
LDL-C (mmol/L) | 2.9 | 2.8 | 2.9 | 3.1 | 0.95†|
 ± 1.2 | [2.2; 3.8] |  ± 0.7 | [2.3; 3.3] | ||
Non-HDL (mmol/L) | 3.7 | 3.5 | 3.4 | 3.6 | 0.52†|
 ± 1.1 | [3.0; 4.6] |  ± 0.8 | [2.8; 3.8] | ||
Lp(a) (nmol/L) | 55 | 33 | 86 | 47 | 0.36‡ |
 ± 58 | [11; 89] |  ± 92 | [17; 161] | ||
Apo B (g/L) | 1.00 | 0.97 | 0.95 | 1.00 | 0.71†|
 ± 0.32 | [0.78; 1.26] |  ± 0.2 | [0.76; 1.09] | ||
PCSK9 (ng/mL) | 78.5 | 76.7 | 100.1 | 85.4 | 0.09†|
 ± 19.3 | [65.2; 94.0] |  ± 39.0 | [68.7; 142.3] | ||
ANGPTL3 (ng/mL) | 94.0 | 93.1 | 104.1 | 110.4 | 0.50†|
 ± 36.2 | [59.4; 132.9] |  ± 31.3 | [78.2; 128.0] | ||
Non-fasting C-peptide (pmol/L) | 860 | 882 | 726 | 554 | 0.51†|
 ± 495 | [356; 1093] |  ± 432 | [371; 982] | ||
Non-fasting Insulin (pmol/L) | 122 | 124 | 97 | 44 | 0.60‡ |
 ± 88 | [25; 186] |  ± 95 | [32; 140] | ||